Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SRPT
CUSIPN/A
Phone617-274-4000
Debt
Debt-to-Equity Ratio0.62
Current Ratio10.88
Quick Ratio9.89
Price-To-Earnings
Trailing P/E Ratio-86.58
Forward P/E Ratio-38.69
P/E GrowthN/A
Sales & Book Value
Annual Sales$154.58 million
Price / Sales61.03
Cash FlowN/A
Price / CashN/A
Book Value$12.21 per share
Price / Book11.63
Profitability
EPS (Most Recent Fiscal Year)($1.64)
Net Income$-50,680,000.00
Net Margins-89.64%
Return on Equity-19.34%
Return on Assets-12.30%
Miscellaneous
Employees255
Outstanding Shares66,440,000
Market Cap$10.73 billion
Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions
What is Sarepta Therapeutics' stock symbol?
Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."
How were Sarepta Therapeutics' earnings last quarter?
Sarepta Therapeutics Inc (NASDAQ:SRPT) posted its quarterly earnings data on Wednesday, August, 8th. The biotechnology company reported ($1.67) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.68) by $0.99. The biotechnology company had revenue of $73.53 million for the quarter, compared to analyst estimates of $71.53 million. Sarepta Therapeutics had a negative return on equity of 19.34% and a negative net margin of 89.64%. The company's quarterly revenue was up 110.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.48) earnings per share. View Sarepta Therapeutics' Earnings History.
When is Sarepta Therapeutics' next earnings date?
What price target have analysts set for SRPT?
25 brokers have issued 12-month price targets for Sarepta Therapeutics' stock. Their forecasts range from $56.51 to $275.00. On average, they anticipate Sarepta Therapeutics' stock price to reach $170.2959 in the next twelve months. This suggests a possible upside of 19.9% from the stock's current price. View Analyst Price Targets for Sarepta Therapeutics.
What is the consensus analysts' recommendation for Sarepta Therapeutics?
25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 2 hold ratings and 23 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sarepta Therapeutics.
What are Wall Street analysts saying about Sarepta Therapeutics stock?
Here are some recent quotes from research analysts about Sarepta Therapeutics stock:
- 1. According to Zacks Investment Research, "Sarepta's Exondys 51 witnessed impressive growth so far this year. Furthermore, a potential marketing approval in EU should boost sales. Sarepta is also focused on reimbursement programs for better accessibility of the drug. The company’s collaboration agreements with Summit Pharmaceuticals and Catabasis as well as its own follow-on exon-skipping and gene therapy pipeline candidates represent the most comprehensive approach to treat DMD. Meanwhile, the settlement of the patent litigation with BioMarin removes a major overhang for Sarepta. However, dependence on a single product, Exondys 51, remains a concern. The DMD market is getting competitive as several other companies are developing treatments. Notably, the company’s shares have outperformed the industry so far this year. Loss estimates have widened ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters." (10/16/2018)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating with a 12-month price target of $217. Today, we received an update at the World Muscle Society meeting around the four patients dosed with AAVrh74.MHCK7.Micro-Dystrophin. At this meeting, biopsy information on patient four and functional data were shared. We reiterate Sarepta as a top pick in small-mid cap, and we also see many catalysts in next 12 months to drive shares higher, as we discussed in our launch, linked here. Robust dystrophin increase has been seen by all measurements, so this technology represents a big step forward in dystrophin production." (10/1/2018)
Who are some of Sarepta Therapeutics' key competitors?
Some companies that are related to Sarepta Therapeutics include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Jazz Pharmaceuticals (JAZZ), Genmab A/S (GNMSF) and Perrigo (PRGO).
Who are Sarepta Therapeutics' key executives?
Sarepta Therapeutics' management team includes the folowing people:
- Mr. Douglas S. Ingram, Pres, CEO & Director (Age 55)
- Mr. Sandesh Mahatme LL.M., Exec. VP, CFO & Chief Bus. Officer (Age 53)
- Mr. David Tyronne Howton Jr., Sr. VP, Gen. Counsel & Corp. Sec. (Age 46)
- Mr. Alexander Bo Cumbo, Sr. VP & Chief Commercial Officer (Age 47)
- Dr. Edward M. Kaye, Advisor (Age 69)
Who are Sarepta Therapeutics' major shareholders?
Sarepta Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State of New Jersey Common Pension Fund D (0.32%), Bank of Montreal Can (0.15%), Tributary Capital Management LLC (0.02%), BB&T Corp (0.01%), Fox Run Management L.L.C. (0.00%) and NJ State Employees Deferred Compensation Plan (0.00%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Edward M Md Kaye, Hans Lennart Rudolf Wigzell, Richard Barry, Sandesh Mahatme and Shamim Ruff. View Institutional Ownership Trends for Sarepta Therapeutics.
Which institutional investors are selling Sarepta Therapeutics stock?
SRPT stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold Sarepta Therapeutics company stock in the last year include Alexander Cumbo, David T Howton, Hans Lennart Rudolf Wigzell, Richard Barry and Shamim Ruff. View Insider Buying and Selling for Sarepta Therapeutics.
Which institutional investors are buying Sarepta Therapeutics stock?
SRPT stock was bought by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Tributary Capital Management LLC, Fox Run Management L.L.C., Nisa Investment Advisors LLC, Atria Investments LLC, NJ State Employees Deferred Compensation Plan, New Jersey Better Educational Savings Trust and BB&T Corp. View Insider Buying and Selling for Sarepta Therapeutics.
How do I buy shares of Sarepta Therapeutics?
Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sarepta Therapeutics' stock price today?
One share of SRPT stock can currently be purchased for approximately $141.99.
How big of a company is Sarepta Therapeutics?
Sarepta Therapeutics has a market capitalization of $10.73 billion and generates $154.58 million in revenue each year. The biotechnology company earns $-50,680,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Sarepta Therapeutics employs 255 workers across the globe.
What is Sarepta Therapeutics' official website?
How can I contact Sarepta Therapeutics?
Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected]
MarketBeat Community Rating for Sarepta Therapeutics (NASDAQ SRPT)
MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe SRPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
